BioCapital
Filter News
Found 43,442 articles
-
Altimmune on Wednesday said it is ending development of HepTcell, a hepatitis B candidate, following disappointing trial results as it focuses on obesity and metabolic dysfunction-associated steatohepatitis.
-
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
3/28/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
-
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
3/28/2024
Emergent BioSolutions Inc. remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies.
-
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
3/28/2024
Processa Pharmaceuticals, Inc. announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.
-
Sirnaomics Announces 2023 Annual Results
3/28/2024
Sirnaomics Ltd., a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023.
-
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
3/28/2024
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced results from a special meeting of stockholders held March 27, 2024.
-
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
3/28/2024
Precigen, Inc. announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis and bring together RRP patients and their caregivers to encourage new connections and build community among those interested in and affected by this devastating disease.
-
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
3/28/2024
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
3/27/2024
KeifeRx announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
-
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
3/27/2024
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
3/27/2024
Avalo Therapeutics, Inc. announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc.
-
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
3/27/2024
Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.
-
AMPEL BioSolutions' Lupus Test Launches to Predict Flares & Drug Targets
3/27/2024
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.
-
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
3/27/2024
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023.
-
Ascentage Pharma Announces 2023 Annual Results
3/27/2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.
-
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
3/27/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
-
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
3/26/2024
Telomir Pharmaceuticals, Inc. announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.
-
A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination
3/26/2024
AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process.
-
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
3/26/2024
United Therapeutics Corporation, a public benefit corporation, announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.